AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin

AIDS. 1992 Dec;6(12):1483-7. doi: 10.1097/00002030-199212000-00010.


Objectives: To evaluate efficacy and tolerance of bleomycin in AIDS-associated mucocutaneous Kaposi's sarcoma. A previous study showed that bleomycin was effective and well tolerated in this setting.

Design: A non-comparative, open, prospective study.

Methods: Seventy patients were treated with 5 mg per day intramuscular bleomycin on 3 consecutive days every 2 weeks.

Results: Two patients achieved a complete response and 50 a partial response (overall response rate, 74%). Median time to treatment response was 4 weeks (range, 2-12 weeks) and median time to relapse 10 weeks (range, 2-36 weeks). Dose-limiting toxicity consisted of cutaneous adverse reactions.

Conclusion: Bleomycin is active against AIDS-associated mucocutaneous Kaposi's sarcoma; relapse occurs after discontinuation of therapy.

Publication types

  • Clinical Trial

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Adult
  • Bleomycin / therapeutic use*
  • Bleomycin / toxicity
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Recurrence
  • Sarcoma, Kaposi / drug therapy*
  • Sarcoma, Kaposi / etiology
  • Survival Analysis
  • Treatment Outcome


  • Bleomycin